Targeted endometrial sampling
Targeted or visually guided sampling, such as hysteroscopy, has been shown to be very accurate in identifying benign pathology, although the sensitivity of hysteroscopic diagnosis of cancer is significantly lower at approximately 50%.11 Therefore, the benefit of hysteroscopy is in complementing the blind nature of D&C by guiding sampling of intracavitary lesions, should they exist.
Hysteroscopy is safe in endometrial cancer and is not associated with upstaging the cancer from transtubal extirpation of malignant cells.12
The addition of hysteroscopy contributes some cost and equipment to the blind D&C procedure; therefore, it might be best applied in cases where there is known intracavitary pathology or inadequate prior sampling. In well-selected patients, hysteroscopy often can be used in an office setting, which improves the practicality of the procedure. Smaller and, in some cases, disposable equipment aids in the feasibility of adding visual guidance to office sampling.
Optimizing sampling
Postmenopausal women have a higher risk for sampling failure, compared with younger women. Obesity also is a risk for failed sampling.13 Cervical ripening with misoprostol may increase access to the endometrial cavity, and ultrasound guidance may decrease the risk of uterine perforation in a stenotic cervix.
Clinicians should ensure that histology results are concordant with clinical data. Discordant results should be reevaluated. For example, if an ultrasound demonstrates a thickened endometrial stripe, but the sampling reveals “scant atrophic tissue,” then there is unexplained pathology to address. Further work-up, such as more comprehensive sampling with hysteroscopy, should be considered in such cases. Additionally, persistent postmenopausal bleeding, despite a benign endometrial biopsy, should be reevaluated over time to rule out occult disease missed during prior sampling.
Dr. Cotangco is a resident in the department of obstetrics and gynecology at the University of Illinois, Chicago. Dr. Rossi is an assistant professor in the division of gynecologic oncology at the University of North Carolina, Chapel Hill. They reported having no relevant financial disclosures.
References
1. Acta Obstet Gynecol Scand. 2004 Feb;83(2):203-7.
2. Menopause Int. 2010 Mar;16(1):5-8.
3. Obstet Gynecol. 2009 Aug;114(2 Pt 1):409-11.
4. Ultrasound Obstet Gynecol. 2004 Oct;24(5):558-65.
5. Ultrasound Obstet Gynecol. 2001 Aug;18(2):157-62.
6. Am J Obstet Gynecol. 2009 Jul;201(1):5-11.
7. Obstet Gynecol Clin North Am. 2000 Jun;27(2):235-44.
8. J Reprod Med. 1995 Aug;40(8):553-5.
9. BJOG. 2008 Jul;115(8):1028-36.
10. PLoS Med. 2016 Dec. doi: 10.1371/journal.pmed.1002206.
11. Arch Gynecol Obstet. 2012 Mar;285(3):839-43.